We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Autolus Therapeutics PLC | NASDAQ:AUTL | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.08 | 1.95% | 4.19 | 3.50 | 7.89 | 4.37 | 4.055 | 4.22 | 1,948,998 | 05:00:07 |
J.P. Morgan and Wells Fargo Securities acted as joint bookrunners for the offering. Kempen & Co, Mizuho Securities and Needham & Company acted as co-managers.
The securities described above were offered by Autolus pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”). A final prospectus supplement to the accompanying prospectus describing the terms of the offering was filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained for free from either of the joint book-running managers for the offering, J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at +1 866 803 9204 or by email at prospectus-eq_fi@jpmchase.com; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 326-5897 or email a request to cmclientsupport@wellsfargo.com. For the avoidance of doubt, such prospectus will not constitute a "prospectus" for the purposes of the Regulation (EU) 2017/1129 and has not been reviewed by any competent authority in any member state in the European Economic Area or the United Kingdom.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About Autolus
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
Contacts:
Lucinda Crabtree, Ph.D.Vice President, Investor Relations and Corporate Communications+44 (0)7587 372 619l.crabtree@autolus.com
Julia Wilson+44 (0)7818 430877j.wilson@autolus.com
Susan A NoonanS.A. Noonan Communications, LLC+1 212 966 3650susan@sanoonan.com
1 Year Autolus Therapeutics Chart |
1 Month Autolus Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions